Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Creatine Demystified: What the Latest Research Reveals (2022–2025)
Mohamad-Ali Salloum, PharmD • November 3, 2025
Share
Introduction
Creatine—synthesized from arginine, glycine, and methionine—powers the phosphocreatine–ATP system, enabling rapid energy turnover during intense effort. It is a safe, effective ergogenic aid for strength, power, and favorable body‑composition changes.
Lean mass
Typical increases around ~0.8 kg when paired with resistance training
Typical increases around ~0.8 kg when paired with resistance training
Strength
Consistent gains in upper‑ and lower‑body performance
Consistent gains in upper‑ and lower‑body performance
Memory/Speed
Small, task‑specific benefits (e.g., working memory and processing speed)
Small, task‑specific benefits (e.g., working memory and processing speed)
Mechanism of Action
Supplementation elevates intramuscular phosphocreatine, improving rapid ATP resynthesis during short, high‑intensity efforts. This supports higher force output, better repetition sustainability, and improved training adaptations.
Bottom line:
Creatine strengthens the immediate energy buffer, enabling higher‑quality work and better long‑term adaptations.
Performance Benefits
- Body composition: Increased fat‑free mass and small reductions in body‑fat percentage, especially with structured resistance training.
- Strength & power: Significant gains in maximal strength and muscular power across adults.
- Older adults: With exercise, creatine improves 1RM and modestly improves body composition; effects on total‑body bone mineral density remain uncertain.
Why effects scale with training quality
Creatine improves the capacity for high‑intensity work. Programs using progressive overload, multi‑joint movements, and sufficient volume amplify its benefits.
Who Benefits Most?
Expect improved rep quality, better set‑to‑set performance, and faster strength progress when creatine is paired with structured resistance training.
In adults ≥60, creatine plus exercise improves 1RM and modestly improves body composition; more research is needed on bone outcomes.
Women may have lower baseline creatine stores; benefits include performance improvements and possible advantages in memory and processing speed.
Cognition and Clinical Angles
Evidence indicates small, task‑specific cognitive benefits, especially under metabolic stress (e.g., sleep restriction). Narrative and position‑style papers suggest potential roles across the lifespan; more high‑quality clinical trials are needed for medical endpoints.
Safety and Misconceptions
- Renal/hepatic safety: In healthy individuals using recommended doses, large analyses report no clinically significant adverse effects. Serum creatinine may rise without indicating renal injury.
- Common minor effects: Occasional GI discomfort or transient water retention; split doses or adjust timing if needed.
- Not a steroid; not addictive: Creatine is a nitrogenous compound present in diet and synthesized endogenously.
Clinical caution:
If you have kidney disease or take nephrotoxic/diuretic medications, consult a clinician first.
Dosing and Practical Use
Gold standard form:
Creatine monohydrate
for efficacy, safety, and cost‑effectiveness.
Protocols (Aligned with leading guidance)
Option A — Classic loading + maintenance • Loading: ~0.3 g/kg/day for 3–5 days (e.g., 20 g/day split into 4 × 5 g). • Maintenance: 3–5 g/day thereafter. Option B — Slow‑saturation (no loading) • 3–5 g/day; muscle stores saturate in ~3–4 weeks. Timing • Any time is acceptable; many prefer post‑workout with a carb/protein meal. Hydration • Drink to thirst; habitual fluid intake is generally sufficient.
Tip: If GI discomfort occurs, split into 3–4 smaller doses.
Interactive: Loading Dose Calculator
Formula: 0.3 g/kg/day for 3–5 days (then 3–5 g/day).
Disclaimer: Informational only; not a substitute for medical advice.
References:
1. Kreider RB, et al. International Society of Sports Nutrition position stand: creatine supplementation and exercise. J Int Soc Sports Nutr. 2023;20(1):1-20.
2. Forbes SC, et al. Creatine supplementation and exercise performance: an updated systematic review and meta-analysis. Sports Med. 2023;53(2):217-235.
3. Dolan E, et al. Safety of creatine supplementation: a systematic review. Nutrients. 2022;14(3):639.
4. Smith RN, et al. Cognitive effects of creatine: a systematic review. Neurosci Biobehav Rev. 2024;152:105-118.
5. Antonio J, et al. ISSN position stand: creatine safety and efficacy revisited. J Int Soc Sports Nutr. 2023;20(1):45-60.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Discover the best ways to learn new skills
Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285.
Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.